Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

About REPROCELL

Make an inquiry

REPROCELL Corporate News (7)

Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others

The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal

Joint Announcement with Ajinomoto Co., Inc. Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free

Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes

Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells

Announcement of Award for Prototype Development of a Liver Cell Kit

Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit

REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).

New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

RSC book publication: Human-based systems for translational research

Biopta and Proteon publish new research in Journal of Cardiovascular Pharmacology

Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca

REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)

Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA)

Scottish company creates first searchable database of human pharmacological responses in functional intact tissues

Subscribe to receive updates